Home › Epithelial Carcinoma ng Ovary › Washington
Pag-aaral pangklinika para sa Epithelial Carcinoma ng Ovary sa Washington
6 pag-aaral para sa Epithelial Carcinoma ng Ovary ang naghahanap ng mga kalahok sa mga site sa Washington.
Mga Lungsod sa Washington
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585, Spokane
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT06890338Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Sacred Heart Medical Center & Children's Hospital, Spokane
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 15, 2026 · NCT06915025AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Seattle
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 21, 2026 · NCT07218809A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Fred Hutchinson Cancer Center, Seattle
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- The Swedish Hospital, Seattle
Nagre-recruitObservasyonal na pag-aaral
Edad 30 pataas · Kababaihan · Na-update Set 16, 2025 · NCT04794322A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT05107674Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.